We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-0.94%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$553M
AUM Growth
-$75.2M
Cap. Flow
-$19.5M
Cap. Flow %
-3.53%
Top 10 Hldgs %
31.54%
Holding
133
New
18
Increased
30
Reduced
36
Closed
26

Top Buys

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$7.68M
2
ANNX icon
Annexon
ANNX
+$7.65M
3
ORA icon
Ormat Technologies
ORA
+$6.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.93M
5
SEDG icon
SolarEdge
SEDG
+$5.77M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$14.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.2M
3
AMZN icon
Amazon
AMZN
+$8.8M
4
S icon
SentinelOne
S
+$6.62M
5
NICE icon
Nice
NICE
+$6.39M

Sector Composition

Rank Sector Weight
1 Healthcare 73.33%
2 Technology 15.86%
3 Communication Services 3.88%
4 Consumer Discretionary 2.48%
5 Utilities 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
26
DELISTED
Apellis Pharmaceuticals
APLS
$6.58M 1.19%
206,251
-9,622
-4% -$289K
IMTX icon
27
Immatics
IMTX
$1.18B
$6.55M 1.18%
921,111
+200,000
+28% +$1.72M
PRAX icon
28
CALL
Praxis Precision Medicines
PRAX
$8.58B
$6.39M 1.15%
83,000
+43,000
+108% +$3.11M
ANNX icon
29
Annexon
ANNX
$834M
$6.38M 1.15%
+1,243,039
New +$7.65M
ABBV icon
30
AbbVie
ABBV
$443B
$6.09M 1.1%
34,256
-3,744
-10% -$688K
MRK icon
31
Merck
MRK
$322B
$5.93M 1.07%
59,600
– –
BHVN icon
32
Biohaven
BHVN
$2.03B
$5.85M 1.06%
156,494
+23,171
+17% +$1.08M
RZLT icon
33
Rezolute
RZLT
$454M
$5.71M 1.03%
1,165,895
-31,043
-3% -$156K
FROG icon
34
JFrog
FROG
$9.66B
$5.6M 1.01%
190,381
+70,000
+58% +$2.12M
DYN icon
35
Dyne Therapeutics
DYN
$4.7B
$5.57M 1.01%
236,262
+179,758
+318% +$5.32M
MRUS
36
DELISTED
Merus
MRUS
$5.49M 0.99%
130,532
-17,101
-12% -$821K
NTLA icon
37
Intellia Therapeutics
NTLA
$1.49B
$5.43M 0.98%
466,080
+175,000
+60% +$2.73M
ORA icon
38
Ormat Technologies
ORA
$6B
$5.35M 0.97%
+79,000
New +$6.1M
KURA icon
39
Kura Oncology
KURA
$800M
$5.31M 0.96%
610,087
– –
ACAD icon
40
Acadia Pharmaceuticals
ACAD
$4.43B
$5.29M 0.96%
288,539
+36,000
+14% +$581K
SEDG icon
41
SolarEdge
SEDG
$2.51B
$5.1M 0.92%
+375,000
New +$5.77M
NVS icon
42
Novartis
NVS
$297B
$4.87M 0.88%
50,000
– –
HELP
43
Cybin Inc
HELP
$485M
$4.75M 0.86%
538,111
-395,114
-42% -$4.01M
SKYE icon
44
Skye Bioscience
SKYE
$20M
$4.43M 0.8%
1,564,628
+1,106
+0.1% +$4.62K
GSK icon
45
GSK
GSK
$104B
$4.4M 0.79%
130,000
+30,000
+30% +$1.08M
ETNB
46
DELISTED
89bio
ETNB
$4.35M 0.79%
556,532
+19,985
+4% +$165K
VIR icon
47
Vir Biotechnology
VIR
$1.46B
$4.27M 0.77%
581,829
+488,500
+523% +$3.85M
DAWN
48
DELISTED
Day One Biopharmaceuticals
DAWN
$4.24M 0.77%
334,987
-12,640
-4% -$176K
VKTX icon
49
Viking Therapeutics
VKTX
$3.7B
$4.16M 0.75%
103,270
-29,796
-22% -$1.7M
PLRX icon
50
Pliant Therapeutics
PLRX
$64.4M
$3.92M 0.71%
297,362
– –
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2024 Portfolio in Review

As of Q4 2024, Sphera Funds Management held 133 positions worth $553M, down 12% from $628M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Sphera Funds Management withdrew a net $19.5M in Q4 2024, closing 26 positions and reducing 36 holdings. Its most notable exit was Apple, an estimated $14.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 70% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Sphera Funds Management opened a new position in Alphabet (Google) Class C worth $8.28M.

  • Sphera Funds Management's largest Q4 2024 buy was Alphabet (Google) Class C: 43,500 shares worth $8.28M.
  • Sphera Funds Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $5.93M increase.
  • Sphera Funds Management's biggest Q4 2024 reduction was Teva Pharmaceuticals, cutting an estimated $10.2M.
  • Sphera Funds Management fully exited Apple in Q4 2024, selling an estimated $14.2M.
  • Sphera Funds Management's ten largest holdings make up 32% of its $553M portfolio in Q4 2024.
  • Sphera Funds Management opened 18 new positions and closed 26 in Q4 2024.
  • Sphera Funds Management's portfolio value fell 12% quarter-over-quarter to $553M.

Based on Sphera Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.